iTolerance is a privately held regenerative medicine company enabling tissue, organoid or cell therapy without the need for life-long immunosuppression. Leveraging our proprietary technology platform, iTOL-100, we are advancing a pipeline of programs using both allogenic pancreatic islets and stem-cells that have the potential to cure diseases. Our lead program, iTOL-101 is being developed for Type 1 Diabetes and in a preclinical non-human primate study, pancreatic islet cells co-implanted with iTOL-101 exhibited long-term function with control of blood glucose levels and restoration of insulin secretion without the use of chronic immune suppression. Our follow-on candidate, iTOL-102 is leveraging significant advancements in stem cells, which allows a potentially inexhaustible supply of insulin-producing cells for use in Type 1 Diabetes. Additionally, the Company is developing iTOL-201 for liver failure and iTOL-301 as a potential regenerative protein and cell therapy that leverages stem cell sources to produce proteins or hormones in the body in conditions of high unmet need.
Company Details
- Employees
- 5
- Founded
- 2020
- Address
- Miami, Fl 33136, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.itolerance.com/
- HQ
- Miami, FL
Itolerance, Inc. Questions
Itolerance, Inc.'s website is https://www.itolerance.com/
Itolerance, Inc.'s LinkedIn profile is https://www.linkedin.com/company/itolerance
Itolerance, Inc. has
5 employees.
View email and phone details for 5
employees at Itolerance, Inc..
Itolerance, Inc.'s industry is
Biotechnology Research
Itolerance, Inc.'s top competitors are
Anima Biotech,
Northway Biotech,
Nls Pharmaceutics Ag,
Myosin Therapeutics Inc.,
Cocrystal Pharma, Inc.,
Aim Immunotech,
Kadimastem Ltd.,
Opko Health, Inc.,
Brainstorm Cell Therapeutics,
Diabetes Research Institute Foundation.
Itolerance, Inc.'s categories are Biotechnology Research
Itolerance, Inc.'s founding year is 2020
